Patients with breast cancer have a higher level of serum free thyroxine (T4) compared with those with benign breast diseases

王亘,陈小松,毛艳,李亚芬,陈伟国,沈坤炜

DOI: https://doi.org/10.3781/j.issn.1000-7431.2014.04.012

2014-01-01

Tumori

Abstract:Objective: To explore the relationship between serum thyroid hormone level and the occurrence of breast cancer. Methods: Peripheral blood samples and the clinicopathological characteristics of 414 patients with breast diseases (219 cases of benign breast diseases and 195 cases of breast cancer) undergoing surgery between August 2012 and November 2012 were collected. The levels of serum total triiodothyronine (TT3), free triiodothyronine (FT3), total thyroxine (TT4), free thyroxine (FT4) and the thyroid-stimulating hormone (TSH) were examined to compare the differences in thyroid function tests between the patients with breast benign diseases and cancer. Results: There were statistically significant differences in age, menopausal status, child-bearing history, breast-feeding history, body mass index (BMI), and serum TT4 and FT4 levels between the patients with breast benign diseases and cancer (P < 0.01). The patients with breast cancer likely had an older age [odds ratio (OR): 1.071, 95% confidence interval (CI): 1.051-1.092, P < 0.001] and a higher serum FT4 level (OR: 1.237, 95% CI: 1.091-1.402, P = 0.001). Conclusion: The patients with breast cancer seem to have higher levels of serum TT4 and FT4, and the high level of serum FT4 may be related to the occurrence of breast cancer. DOI:10.3781/j.issn.1000-7431.2014.04.012